RhumbLine Advisers’s Eledon Pharmaceuticals ELDN Stock Holding History

RhumbLine Advisers’s Portfolio ELDN Stock Details ELDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$349K	Buy	88,609 +40,983	+86%	+$149K	﹤0.01%	2979
2026 Q1	$147K	Buy	47,626 +3,009	+7%	+$7.09K	﹤0.01%	3253
2025 Q4	$67.4K	Sell	44,617 -8,947	-17%	-$21.3K	﹤0.01%	3581
2025 Q3	$139K	Sell	53,564 -2,486	-4%	-$7.27K	﹤0.01%	3388
2025 Q2	$152K	Buy	+56,050	New	+$168K	﹤0.01%	3375
2017 Q2	–	Sell	-197	Closed	-$27K	–	2932
2017 Q1	$27K	Buy	+197	New	+$28.9K	﹤0.01%	2838
2016 Q2	–	Sell	-70	Closed	-$64K	–	2992
2016 Q1	$64K	Buy	70 +3	+4%	+$2.94K	﹤0.01%	2949
2015 Q4	$94K	Buy	67 +5	+8%	+$8.71K	﹤0.01%	2962
2015 Q3	$104K	Buy	+62	New	+$128K	﹤0.01%	2940

Other funds holding ELDN

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DCM

Defilade Capital Management Emeryville, California $747M AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

CCM

Catalio Capital Management New York $532M AUM 171.17% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Zimmer Partners New York $4.34B AUM 22.78% 1-Year Est. Return

RhumbLine Advisers's ELDN Position: Q2 2026 in Review

RhumbLine Advisers increased its Eledon Pharmaceuticals (ELDN) stake by 86% in Q2 2026, buying an estimated $149K and bringing the position to 88,609 shares worth $349K. The position accounts for ﹤0.01% of the portfolio, ranked #2979.

RhumbLine Advisers first reported a position in ELDN in Q3 2015 and has held it in 9 quarters since. 161 funds tracked by Wall St. Rank hold ELDN as of Q2 2026.

RhumbLine Advisers held 88,609 shares of Eledon Pharmaceuticals worth $349K as of Q2 2026.
RhumbLine Advisers bought 40,983 Eledon Pharmaceuticals shares in Q2 2026, an estimated $149K.
Eledon Pharmaceuticals made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #2979 holding.
RhumbLine Advisers first reported a position in Eledon Pharmaceuticals in Q3 2015 and has held it in 9 quarters since.
161 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.